GlassScriptPhysician profile
Lim L Taw
NPI 1720205008
$5,057.91
in general payments reported to CMS, 2019-2025
19 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $622 · 2021: $599 · 2022: $611 · 2023: $670 · 2024: $1,456 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,001.34 | 2022-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.03 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $675.24 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $658.76 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $290.58 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Watermark Medical, INC. | $278.40 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.01 | 2021-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $181.94 | 2021 | |
| Optinose US, INC. | $152.10 | 2024 | |
| Alexion Pharmaceuticals, INC. | $131.81 | 2024 | Ultomiris |
| Novo Nordisk INC | $121.88 | 2019 | |
| Philips North America LLC | $105.03 | 2019-2020 | |
| Amarin Pharma, INC. | $82.88 | 2019-2021 | |
| Pfizer INC. | $67.27 | 2023-2025 | |
| Gilead Sciences, INC. | $33.24 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $32.89 | 2020 | |
| Sumitomo Pharma America, INC. | $31.62 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $23.18 | 2021 | |
| Abbvie INC. | $21.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lim Taw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.